Transparency Market Research Report Added "Chronic Kidney Disease Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" to its database.
Albany, NY -- (SBWIRE) -- 07/03/2014 -- Chronic kidney disease (CKD), which is also known as chronic renal disease, is caused due to progressive loss of proper functioning of the kidneys and associated renal system over a longer period of time either months or years. Chronic kidney diseases often go unnoticed, as the individuals suffering from the disease are seen to be having non-specific symptoms like feeling unwell, or loss of appetite among others. Many a times, patients suffering from a chronic kidney disorder are diagnosed due to their screening for diabetes, high blood pressure and others.
Browse the full report with request TOC at http://www.transparencymarketresearch.com/chronic-kidney-disease.html
However, patients suffering from this chronic disease also suffer from other disorders and show symptoms of diseases, such as, cardiovascular disease, pericarditis, and anemia. A chronic kidney disease has been classified into five major stages of the severity of the disease, where the first stage represents mildest disease condition and the fifth stage with most severe conditions that may lead to death. CKD market is bound to experience high growth in the near future as most of the big pharmaceutical companies are doing extensive research on developing new and specific drugs for the disease. Disease diagnostic tests as well as test kits and others will also grow with the growing demand from this CKD market.
Major driving factors for the growth of this market include, increasing incidences and prevalence of chronic kidney disease worldwide, rising demand for advanced diagnostics and therapeutics for the disease, aging population and increasing number of individuals suffering from diabetes, high blood pressure etc. Increasing number of people suffering from disorders like diabetes, high blood pressure, and others are also contributing towards the increasing incidence rate and prevalence of CKD worldwide. According to CDC, U.S. more than 26 million people in the U.S. were suffering from CKD in 2006 and around 45,000 people died of it in the same year. It was also estimated that around 44% of the patients suffering from CKD are due to their diabetes condition and around 28% of them had the disease due to their high blood pressure.
Buy This Report with 10% Discount and Customize as per Your Requirement @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2481
Thus, the increasing prevalence of the disease will continue to demand more form this market, hence will contribute towards the growth of this market in future. But, patent expiries of some of the major branded drugs for late stage CKD and changing reimbursement scenario in some of the major markets like the U.S., U.K. and others may restrain the growth of this market. However, increasing awareness and affordability of the people across geographies along with the launch of some of the pipelined drugs in the coming future will provide boost to the growth of this market in future.
Geographically, North America holds the leading position in the global CKD market followed by the European market. Major factors responsible for the growth of this market in the region are high prevalence of the disease especially in the U.S., well-established healthcare infrastructure, and high affordability and awareness levels of the people of these regions. Asia-Pacific region is expected to show high growth in the near future due to increasing number of diabetic and high blood pressure patients that ultimately lead to CKD, rising healthcare awareness in the region and increasing demand for advanced diagnostics and therapeutics for CKD in the region.
Some of the major players operating in the CKD market are Acceleron Pharma, Inc., Amgen, Inc., AstraZeneca plc, Eli Lilly and Company, Evotec AG, OPKO Health, Inc., Quark Pharmaceuticals, Inc., Nippon Zoki Pharmaceutical Co., Ltd., Panion & Bf Biotech, Inc., Vifor Pharma AG, and Sanofi.
90 State Street,
Albany NY - 12207